Brind.

Adaptive Biotechnologies Presents New Consensus Definition for Multiple Myeloma Cure

2 reports, 1 independent Updated Fri 00:00
No new developments lately Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Adaptive Biotechnologies presented findings at the International Myeloma Society (IMS) 23rd Annual Meeting in Glasgow, Scotland. The company highlighted a new consensus definition regarding a cure for multiple myeloma, a disease that has long been considered incurable. This definition establishes that a patient with newly diagnosed or relapsed disease may be considered cured after five years in complete remission without any myeloma treatment, provided specific criteria are met.

From finanznachrichten.de

Why it matters

Some supportBrind's analysis of the reports

The consensus definition centers on sustained measurable residual disease (MRD) negativity. This establishes a clear standard for determining when a long-term deep response has endured in the disease.

From finanznachrichten.de

Who's involved

  • Adaptive BiotechnologiesCommercial stage biotechnology company focused on diagnosing and treating disease using adaptive immune system genetics.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story